These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.

The formulation in 960 mg and 720 mg prefilled syringes delivers sustained plasma concentrations comparable to those demonstrated in studies with Abilify Maintena.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

Those seeking abortion were found to have triple the risk of a psychiatric disorder compared to the general population.

The findings suggest that reduced gray matter is not the cause of psychiatric illness, although it is found in regions of the brain associated with it.

The atypical antipsychotic is an extended-release injectable suspension that is administered bi-weekly.

Psilocybin is derived from certain types of mushrooms and has been proven to affect serotonin receptors.

Cariprazine (Vraylar; AbbVie, Gedeon Richter) is indicated as an adjunctive therapy to antidepressants for treating adult patients with major depressive disorder.

Investing in outpatient behavioral health treatment pathways found to be a cost-effective measure to better manage both medical and behavioral conditions.

Experts discuss the clinical and economic impact of misdiagnosing bipolar I disorder as major depressive disorder.

Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.

Study results show that the risk of gaining 10% or more of body weight from the baseline fell 50% when patients were on the combination.

Symbyax combines olanzapine, an atypical antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive episodes associated with bipolar I disorder in adults.

The analysis, results of which are published in The Lancer Psychiatry, also identifies genetic markers that seem to influence how quickly the body eliminates the medication from its system.

Risperidone (Risperdal Consta) is an atypical antipsychotic that can treat schizophrenia, bipolar disorder, and irritability caused by autism.

Intra Cellular Therapies’ Lumateperone is available in the 10.5- and 21-mg strengths and can also be used to treat depressive episodes associated with bipolar I or II disorder.

BioXcel plans to launch Igalmi sublingual film in the United States in the second quarter of 2022.

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.